respiratory
Medicines

NOAC reversal agents shouldn’t replace common sense


Last week’s FDA approval of a specific reversal agent for dabigatran and progress in specific antidotes to rivaroxaban and apixaban is reassuring for clinicians but it should not obscure the fact that these drugs are inherently safer than warfarin, says Professor Mark Crowther from McMaster University in Hamilton, Canada. Idarucizumab, which reverses the direct thrombin inhibition ...

Already a member?

Enter your email to keep reading.


OR